Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2020

20.01.2020 | Epidemiology

Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients

verfasst von: Oluwadamilola M. Fayanju, Yi Ren, Rachel A. Greenup, Jennifer K. Plichta, Laura H. Rosenberger, Jeremy Force, Gita Suneja, Gayathri R. Devi, Tari A. King, Faina Nakhlis, Terry Hyslop, E. Shelley Hwang

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Inflammatory breast cancer (IBC) is an aggressive variant for which axillary lymph node (LN) dissection following neoadjuvant chemotherapy (NACT) remains standard of care. But with increasingly effective systemic therapy, it is unclear whether more limited axillary surgery may be appropriate in some IBC patients. We sought to examine whether extent of axillary LN surgery was associated with overall survival (OS) for IBC.

Methods

Female breast cancer patients with non-metastatic IBC (cT4d) diagnosed 2010–2014 were identified in the National Cancer Data Base. Cox proportional hazards modeling was used to estimate the association between extent of axillary surgery (≤ 9 vs ≥ 10 LNs removed) and OS after adjusting for covariates, including post-NACT nodal status (ypN0 vs ypN1-3) and radiotherapy receipt (yes/no).

Results

3471 patients were included: 597 (17.2%) had cN0 disease, 1833 (52.8%) had cN1 disease, and 1041 (30%) had cN2-3 disease. 49.9% of cN0 patients were confirmed to be ypN0 on post-NACT surgical pathology. Being ypN0 (vs ypN1-3) was associated with improved adjusted OS for all patients. Radiotherapy was associated with improved adjusted OS for cN1 and cN2-3 patients but not for cN0 patients. Regardless of ypN status, there was a trend towards improved adjusted OS with having ≥ 10 (vs ≤ 9) LNs removed for cN2-3 patients (HR 0.78, 95% CI 0.60–1.01, p = 0.06) but not for cN0 patients (p = 0.83).

Conclusions

A majority of IBC patients in our study presented with node-positive disease, and for those presenting with cN2-3 disease, more extensive axillary surgery is potentially associated with improved survival. For cN0 patients, however, more extensive axillary surgery was not associated with a survival benefit, suggesting an opportunity for more personalized care.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97(13):966–975CrossRef Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97(13):966–975CrossRef
2.
Zurück zum Zitat van Uden DJP, van Laarhoven HWM, Westenberg AH, de Wilt JHW, Blanken-Peeters CFJM (2015) Inflammatory breast cancer: an overview. Crit Rev Oncol/Hematol. 93(2):116–126CrossRef van Uden DJP, van Laarhoven HWM, Westenberg AH, de Wilt JHW, Blanken-Peeters CFJM (2015) Inflammatory breast cancer: an overview. Crit Rev Oncol/Hematol. 93(2):116–126CrossRef
4.
Zurück zum Zitat Gianni L, Pienkowski T, Im Y-H et al (2016) 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 17(6):791–800CrossRef Gianni L, Pienkowski T, Im Y-H et al (2016) 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 17(6):791–800CrossRef
5.
Zurück zum Zitat Nahleh ZA, Barlow WE, Hayes DF et al (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158(3):485–495CrossRef Nahleh ZA, Barlow WE, Hayes DF et al (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158(3):485–495CrossRef
6.
Zurück zum Zitat Nakhlis F, Regan MM, Warren LE et al (2017) The impact of residual disease after preoperative systemic therapy on clinical outcomes in patients with inflammatory breast cancer. Ann Surg Oncol 24(9):2563–2569CrossRef Nakhlis F, Regan MM, Warren LE et al (2017) The impact of residual disease after preoperative systemic therapy on clinical outcomes in patients with inflammatory breast cancer. Ann Surg Oncol 24(9):2563–2569CrossRef
7.
Zurück zum Zitat Devi GR, Hough H, Barrett N et al (2019) Perspectives on inflammatory breast cancer (IBC) research, clinical management and community engagement from the Duke IBC consortium. J Cancer. 10(15):3344–3351CrossRef Devi GR, Hough H, Barrett N et al (2019) Perspectives on inflammatory breast cancer (IBC) research, clinical management and community engagement from the Duke IBC consortium. J Cancer. 10(15):3344–3351CrossRef
8.
Zurück zum Zitat Classe JM, Bordes V, Campion L et al (2009) Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol: Off J Am Soc Clin Oncol 27(5):726–732CrossRef Classe JM, Bordes V, Campion L et al (2009) Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol: Off J Am Soc Clin Oncol 27(5):726–732CrossRef
9.
Zurück zum Zitat Mamounas EP, Brown A, Anderson S et al (2005) Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol: Off J Am Soc Clin Oncol 23(12):2694–2702CrossRef Mamounas EP, Brown A, Anderson S et al (2005) Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol: Off J Am Soc Clin Oncol 23(12):2694–2702CrossRef
10.
Zurück zum Zitat van der Heiden-van der Loo M, de Munck L, Sonke GS et al (2015) Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: identification rate and influence on axillary treatment. Eur J Cancer. 51(8):915–921CrossRef van der Heiden-van der Loo M, de Munck L, Sonke GS et al (2015) Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: identification rate and influence on axillary treatment. Eur J Cancer. 51(8):915–921CrossRef
11.
Zurück zum Zitat Boileau JF, Poirier B, Basik M et al (2015) Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol: Off J Am Soc Clin Oncol. 33(3):258–264CrossRef Boileau JF, Poirier B, Basik M et al (2015) Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol: Off J Am Soc Clin Oncol. 33(3):258–264CrossRef
12.
Zurück zum Zitat Boughey JC, Suman VJ, Mittendorf EA et al (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (alliance) clinical trial. JAMA 310(14):1455–1461CrossRef Boughey JC, Suman VJ, Mittendorf EA et al (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (alliance) clinical trial. JAMA 310(14):1455–1461CrossRef
13.
Zurück zum Zitat Kuehn T, Bauerfeind I, Fehm T et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 14(7):609–618CrossRef Kuehn T, Bauerfeind I, Fehm T et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 14(7):609–618CrossRef
14.
Zurück zum Zitat Imeokparia FO, Hughes TM, Dossett LA, Jeruss JS, Chang AE, Sabel MS (2019) Axillary pathologic complete response in inflammatory breast cancer patients: implications for SLNB? Ann Surg Oncol 26(10):3374–3379CrossRef Imeokparia FO, Hughes TM, Dossett LA, Jeruss JS, Chang AE, Sabel MS (2019) Axillary pathologic complete response in inflammatory breast cancer patients: implications for SLNB? Ann Surg Oncol 26(10):3374–3379CrossRef
15.
Zurück zum Zitat Gianni L, Eiermann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375(9712):377–384CrossRef Gianni L, Eiermann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375(9712):377–384CrossRef
18.
Zurück zum Zitat Bilimoria KY, Bentrem DJ, Hansen NM et al (2009) Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 27(18):2946–2953CrossRef Bilimoria KY, Bentrem DJ, Hansen NM et al (2009) Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 27(18):2946–2953CrossRef
19.
Zurück zum Zitat Rosenberger LH, Ren Y, Thomas SM, et al. Axillary lymph node dissection in node-positive breast cancer: are 10-nodes adequate and when is enough, enough? Breast Cancer Res Treat 2019 Nov 18 [Epub ahead of print]. Rosenberger LH, Ren Y, Thomas SM, et al. Axillary lymph node dissection in node-positive breast cancer: are 10-nodes adequate and when is enough, enough? Breast Cancer Res Treat 2019 Nov 18 [Epub ahead of print].
20.
Zurück zum Zitat Hidar S, Bibi M, Gharbi O et al (2009) Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer. Int J Surg (London, England). 7(3):272–275CrossRef Hidar S, Bibi M, Gharbi O et al (2009) Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer. Int J Surg (London, England). 7(3):272–275CrossRef
21.
Zurück zum Zitat Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN (2002) Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 9(3):235–242CrossRef Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN (2002) Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 9(3):235–242CrossRef
22.
Zurück zum Zitat DeSnyder SM, Mittendorf EA, Le-Petross C et al (2018) Prospective feasibility trial of sentinel lymph node biopsy in the setting of inflammatory breast cancer. Clin Breast Cancer. 18(1):e73–e77CrossRef DeSnyder SM, Mittendorf EA, Le-Petross C et al (2018) Prospective feasibility trial of sentinel lymph node biopsy in the setting of inflammatory breast cancer. Clin Breast Cancer. 18(1):e73–e77CrossRef
23.
Zurück zum Zitat Caretta-Weyer H, Sisney GA, Beckman C et al (2012) Impact of axillary ultrasound and core needle biopsy on the utility of intraoperative frozen section analysis and treatment decision making in women with invasive breast cancer. Am J Surg. 204(3):308–314CrossRef Caretta-Weyer H, Sisney GA, Beckman C et al (2012) Impact of axillary ultrasound and core needle biopsy on the utility of intraoperative frozen section analysis and treatment decision making in women with invasive breast cancer. Am J Surg. 204(3):308–314CrossRef
24.
Zurück zum Zitat Britton PD, Provenzano E, Barter S et al (2009) Ultrasound guided percutaneous axillary lymph node core biopsy: how often is the sentinel lymph node being biopsied? Breast 18(1):13–16CrossRef Britton PD, Provenzano E, Barter S et al (2009) Ultrasound guided percutaneous axillary lymph node core biopsy: how often is the sentinel lymph node being biopsied? Breast 18(1):13–16CrossRef
25.
Zurück zum Zitat Caudle AS, Yang WT, Krishnamurthy S et al (2016) Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol: Off J Am Soc Clin Oncol. 34(10):1072–1078CrossRef Caudle AS, Yang WT, Krishnamurthy S et al (2016) Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol: Off J Am Soc Clin Oncol. 34(10):1072–1078CrossRef
26.
Zurück zum Zitat Boughey JC, Ballman KV, Le-Petross HT et al (2016) Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0–T4, N1–N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (alliance). Ann Surg 263(4):802–807CrossRef Boughey JC, Ballman KV, Le-Petross HT et al (2016) Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0–T4, N1–N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (alliance). Ann Surg 263(4):802–807CrossRef
27.
Zurück zum Zitat Fayanju OM, Ren Y, Thomas SM et al (2018) The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB). Ann Surg 268(4):591–601CrossRef Fayanju OM, Ren Y, Thomas SM et al (2018) The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB). Ann Surg 268(4):591–601CrossRef
Metadaten
Titel
Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients
verfasst von
Oluwadamilola M. Fayanju
Yi Ren
Rachel A. Greenup
Jennifer K. Plichta
Laura H. Rosenberger
Jeremy Force
Gita Suneja
Gayathri R. Devi
Tari A. King
Faina Nakhlis
Terry Hyslop
E. Shelley Hwang
Publikationsdatum
20.01.2020
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05529-1

Weitere Artikel der Ausgabe 1/2020

Breast Cancer Research and Treatment 1/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.